Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Hepatitis B Virus Genetic Variation and TP53 R249S Mutation in Patients with Hepatocellular Carcinoma in Thailand

  • Thongbai, Chureeporn (Department of Biochemistry, Faculty of Medicine, Chulalongkorn University) ;
  • Sa-nguanmoo, Pattaratida (Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University) ;
  • Kranokpiruk, Pavanrat (Department of Radiology, Faculty of Medicine, Chulalongkorn University) ;
  • Poovorawan, Kittiyod (Department of Medicine, Faculty of Medicine, Chulalongkorn University) ;
  • Poovorawan, Yong (Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University) ;
  • Tangkijvanich, Pisit (Department of Biochemistry, Faculty of Medicine, Chulalongkorn University)
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Chronic hepatitis B virus (HBV) infection and dietary exposure to aflatoxin B1 (AFB1) are major risk factors for hepatocellular carcinoma (HCC). The aim of this study was to evaluate the role of HBV genetic variation and the R249S mutation of the p53 gene, a marker of AFB1-induced HCC, in Thai patients chronically infected with HBV. Sixty-five patients with and 89 patients without HCC were included. Viral mutations and R249S mutation were characterized by direct sequencing and restriction fragment length polymorphism (RFLP) in serum samples, respectively. The prevalences of T1753C/A/G and A1762T/G1764A mutations in the basal core promotor (BCP) region were significantly higher in the HCC group compared to the non-HCC group. R249S mutation was detected in 6.2% and 3.4% of the HCC and non-HCC groups, respectively, which was not significantly different. By multiple logistic regression analysis, the presence of A1762T/G1764A mutations was independently associated with the risk of HCC in Thai patients.

Keywords

References

  1. Bruix J, Sherman M (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208-36. https://doi.org/10.1002/hep.20933
  2. Chen BF, Liu CJ, Jow GM, et al (2006). High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology, 130, 1153-68. https://doi.org/10.1053/j.gastro.2006.01.011
  3. Chen CH, Changchien CS, Lee CM, et al (2008). Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J Infectious Diseases, 198, 1634-42. https://doi.org/10.1086/592990
  4. Choi MS, Kim DY, Lee DH, et al (2007). Clinical significance of pre-S mutations in patients with genotype C hepatitis B virus infection. J Viral Hepat, 14, 161-8. https://doi.org/10.1111/j.1365-2893.2006.00784.x
  5. Chotiyaputta W, Lok AS (2009). Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol, 6, 453-62. https://doi.org/10.1038/nrgastro.2009.107
  6. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma--current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52. https://doi.org/10.7314/APJCP.2012.13.3.743
  7. Gouas D, Shi H,Hainaut P (2009). The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer letters, 286, 29-37. https://doi.org/10.1016/j.canlet.2009.02.057
  8. Hsieh YH, Su IJ, Wang HC, et al (2004). Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis, 25, 2023-32. https://doi.org/10.1093/carcin/bgh207
  9. Hunt CM, McGill JM, Allen MI, et al (2000). Clinical relevance of hepatitis B viral mutations. Hepatology, 31, 1037-44. https://doi.org/10.1053/he.2000.6709
  10. Hussain SP, Schwank J, Staib F, et al (2007). TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene, 26, 2166-76. https://doi.org/10.1038/sj.onc.1210279
  11. Jackson PE, Kuang SY, Wang JB, et al (2003). Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis, 24, 1657-63. https://doi.org/10.1093/carcin/bgg101
  12. Kao JH, Chen PJ, Lai MY, et al (2003). Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology, 124, 327-34. https://doi.org/10.1053/gast.2003.50053
  13. Kay A, Zoulim F (2007). Hepatitis B virus genetic variability and evolution. Virus Research, 127, 164-76. https://doi.org/10.1016/j.virusres.2007.02.021
  14. Kim BK, Revill PA, Ahn SH (2011). HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther, 16, 1169-86. https://doi.org/10.3851/IMP1982
  15. Kirk GD, Lesi OA, Mendy M, et al (2005). 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene, 24, 5858-67. https://doi.org/10.1038/sj.onc.1208732
  16. Kuang SY, Jackson PE, Wang JB, et al (2004). Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA, 101, 3575-80. https://doi.org/10.1073/pnas.0308232100
  17. Kuang SY, Lekawanvijit S, Maneekarn N, et al (2005). Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev, 14, 380-4. https://doi.org/10.1158/1055-9965.EPI-04-0380
  18. Liu Y, Wu F (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect, 118, 818-24. https://doi.org/10.1289/ehp.0901388
  19. Malmassari SL, Deng Q, Fontaine H, et al (2007). Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. Hepatology, 45, 1199-209. https://doi.org/10.1002/hep.21594
  20. Ortiz-Cuaran S, Villar S, Gouas D, et al (2013). Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a casecontrol study from Thailand. Cancer Letters, 331, 46-51. https://doi.org/10.1016/j.canlet.2012.11.012
  21. Sa-Nguanmoo P, Tangkijvanich P, Thawornsuk N, et al (2010). Molecular epidemiological study of hepatitis B virus among migrant workers from Cambodia, Laos, and Myanmar to Thailand. J Med Virology, 82, 1341-9. https://doi.org/10.1002/jmv.21828
  22. Suwannakarn K, Tangkijvanich P, Thawornsuk N, et al (2008). Molecular epidemiological study of hepatitis B virus in Thailand based on the analysis of pre-S and S genes. Hepatol Res, 38, 244-51. https://doi.org/10.1111/j.1872-034X.2007.00254.x
  23. Szymanska K, Chen JG, Cui Y, et al (2009). TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomarkers Prev, 18, 1638-43. https://doi.org/10.1158/1055-9965.EPI-08-1102
  24. Szymanska K, Lesi OA, Kirk GD, et al (2004). Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer, 110, 374-9. https://doi.org/10.1002/ijc.20103
  25. Takahashi K, Ohta Y, Kanai K, et al (1999). Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Archives of Virology, 144, 1299-308. https://doi.org/10.1007/s007050050588
  26. Villar S, Le Roux-Goglin E, Gouas DA, et al (2011). Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection. Environ Health Perspect, 119, 1635-40. https://doi.org/10.1289/ehp.1103539
  27. Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, et al (2012). Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS One, 7, 37707. https://doi.org/10.1371/journal.pone.0037707
  28. Wai CT, Fontana RJ (2004). Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis, 8, 321-52. https://doi.org/10.1016/j.cld.2004.02.006
  29. Wild CP,Montesano R (2009). A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Letters, 286, 22-8. https://doi.org/10.1016/j.canlet.2009.02.053
  30. Yu MC,Yuan JM (2004). Environmental factors and risk for hepatocellular carcinoma. Gastroenterology, 127, 72-8. https://doi.org/10.1016/j.gastro.2004.09.018
  31. Yuen MF, Tanaka Y, Shinkai N, et al (2008). Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut, 57, 98-102.

Cited by

  1. Prevalence of Aflatoxin Induced p53 Mutation at Codon 249 (R249s) in Hepatocellular Carcinoma Patients with and without Hepatitis B Surface Antigen (HBsAg) vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7675
  2. The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients vol.14, pp.9, 2013, https://doi.org/10.3390/ijms140918925
  3. Tissue Microarray Immunohistochemical Profiles of p53 and pRB in Hepatocellular Carcinoma and Hepatoblastoma vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3959
  4. Association of Single Nucleotide Polymorphism rs1053004 in Signal Transducer and Activator of Transcription 3 (STAT3) with Susceptibility to Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.5069
  5. Clinical significance of hepatitis B surface antigen mutants vol.7, pp.27, 2015, https://doi.org/10.4254/wjh.v7.i27.2729
  6. Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus vol.243, pp.2, 2017, https://doi.org/10.1002/path.4938